2020
Fractal Dimension Analysis of Widefield Choroidal Vasculature as Predictor of Stage of Macular Degeneration
Young BK, Kovacs KD, Adelman RA. Fractal Dimension Analysis of Widefield Choroidal Vasculature as Predictor of Stage of Macular Degeneration. Translational Vision Science & Technology 2020, 9: 22-22. PMID: 32832228, PMCID: PMC7414655, DOI: 10.1167/tvst.9.7.22.Peer-Reviewed Original ResearchMeSH KeywordsChoroidFluorescein AngiographyFractalsHumansMacular DegenerationRetrospective StudiesUnited StatesThe new Myopic Traction Maculopathy Staging System
Parolini B, Palmieri M, Finzi A, Besozzi G, Lucente A, Nava U, Pinackatt S, Adelman R, Frisina R. The new Myopic Traction Maculopathy Staging System. European Journal Of Ophthalmology 2020, 31: 1299-1312. PMID: 32506945, DOI: 10.1177/1120672120930590.Peer-Reviewed Original Research
2019
Interactions of the choroid, Bruch's membrane, retinal pigment epithelium, and neurosensory retina collaborate to form the outer blood-retinal-barrier
Fields M, Del Priore LV, Adelman RA, Rizzolo LJ. Interactions of the choroid, Bruch's membrane, retinal pigment epithelium, and neurosensory retina collaborate to form the outer blood-retinal-barrier. Progress In Retinal And Eye Research 2019, 76: 100803. PMID: 31704339, DOI: 10.1016/j.preteyeres.2019.100803.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAge-Related Macular Degeneration Preferred Practice Pattern®
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, Ying GS. Age-Related Macular Degeneration Preferred Practice Pattern®. Ophthalmology 2019, 127: p1-p65. PMID: 31757502, DOI: 10.1016/j.ophtha.2019.09.024.Peer-Reviewed Original ResearchAcademies and InstitutesAgedAngiogenesis InhibitorsColoring AgentsFemaleFluorescein AngiographyHumansIndocyanine GreenIntravitreal InjectionsLaser CoagulationMacular DegenerationMaleOphthalmologyPractice Patterns, Physicians'Quality of Health CareTomography, Optical CoherenceUnited StatesVascular Endothelial Growth Factor A
2017
Novel therapeutics for Stargardt disease
Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. Graefe's Archive For Clinical And Experimental Ophthalmology 2017, 255: 1057-1062. PMID: 28285324, DOI: 10.1007/s00417-017-3619-8.Peer-Reviewed Original ResearchConceptsStargardt diseaseVision lossABCA4 geneStem cell transplantationSevere vision lossPromising treatment candidateNovel therapeutic strategiesRetinal pigment epitheliumStem cell therapyVisual acuityStandard treatmentMacular degenerationTreatment candidatesHESC-RPE cellsStargardt patientsTherapeutic strategiesPharmacological agentsPigment epitheliumMacular dystrophyNovel therapeuticsPatientsDiseaseVisual cyclePrevalent formSecond decade
2016
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients
Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology 2016, 124: 352-358. PMID: 27890437, DOI: 10.1016/j.ophtha.2016.10.036.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsBevacizumabCohort StudiesDatabases, FactualDiabetic RetinopathyDrug UtilizationFemaleHumansInsurance, HealthIntravitreal InjectionsMacular DegenerationMaleMedicare Part CMiddle AgedOphthalmologyPrivate SectorRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal Vein OcclusionRetrospective StudiesUnited StatesVascular Endothelial Growth Factor AYoung AdultConceptsAge-related macular degenerationDiabetic retinal diseaseAnti-VEGF injectionsIntravitreal anti-VEGF injectionsRetinal vein occlusionAdministrative claims dataRetinal diseasesOphthalmic diseasesVein occlusionClaims dataUse of bevacizumabCurrent Procedural Terminology codesPatients 18 yearsRetrospective cohort studyMedicare Advantage patientsOptumLabs Data WarehouseDrug Administration approvalProcedural Terminology codesGrowth factor useRanibizumab useBevacizumab useAvailable medicationsCohort studyMedication useCommon medicationsHyperacuity Exam Screens for Choroidal Neovascularization in Age-Related Macular Degeneration on a Mobile Device.
Chen JS, Adelman RA. Hyperacuity Exam Screens for Choroidal Neovascularization in Age-Related Macular Degeneration on a Mobile Device. Ophthalmic Surgery Lasers And Imaging Retina 2016, 47: 708-15. PMID: 27548447, DOI: 10.3928/23258160-20160808-03.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overChoroidChoroidal NeovascularizationComputers, HandheldCross-Sectional StudiesEquipment DesignFemaleFluorescein AngiographyFundus OculiHumansMacular DegenerationMaleMiddle AgedMobile ApplicationsMonitoring, PhysiologicReproducibility of ResultsTomography, Optical CoherenceVisual AcuityConceptsAge-related macular degenerationChoroidal neovascularizationMacular degenerationSpectral-domain optical coherence tomographySingle-center studyProgression of diseaseOptical coherence tomographyChart reviewTimely treatmentPatientsCoherence tomographyNeovascularizationPatient informationSame dayTreatmentPotential screenFurther dataHuman Research Protection ProgramDegenerationSubspecialistsDiseaseProgression
2014
Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients
Hall LB, Zebardast N, Huang JJ, Adelman RA. Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients. Journal Of Ocular Pharmacology And Therapeutics 2014, 30: 346-352. PMID: 24552305, DOI: 10.1089/jop.2013.0188.Peer-Reviewed Original ResearchMeSH KeywordsAged, 80 and overAntibodies, Monoclonal, HumanizedBevacizumabFemaleHumansIntravitreal InjectionsMacular DegenerationMaleRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinaRetrospective StudiesTomography, Optical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityConceptsAge-related macular degenerationCentral macular thicknessAflibercept injectionsInitial visitMacular degenerationAnti-vascular endothelial growth factor treatmentNeovascular age-related macular degenerationEndothelial growth factor treatmentCentral macular edemaIntraocular pressure increaseSubset of patientsMain outcome measuresOptical coherence tomographyGrowth factor treatmentMacular thicknessNeovascular AgeOcular hypertensionSubmacular fluidVisual outcomeMacular edemaRetrospective studyVisual acuityOutcome measuresStudy populationPatients
2010
Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections
Adelman RA, Zheng Q, Mayer HR. Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections. Journal Of Ocular Pharmacology And Therapeutics 2010, 26: 105-110. PMID: 20187807, DOI: 10.1089/jop.2009.0076.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInjections, IntraocularIntraocular PressureMacular DegenerationMaleOcular HypertensionRanibizumabRetrospective StudiesTime FactorsVascular Endothelial Growth Factor AVitreous BodyConceptsAge-related macular degenerationPersistent ocular hypertensionOcular hypertensionIntraocular pressureIntravitreal bevacizumabRanibizumab injectionsIntravitreal injectionPrevious diagnosisGlaucoma/ocular hypertensionIntravitreal anti-VEGF injectionsAnti-VEGF injectionsIntravitreal bevacizumab injectionPostinjection intraocular pressurePreinjection intraocular pressureMultiple intravitreal injectionsTertiary referral centerRetrospective case seriesElevated intraocular pressureBevacizumab injectionIntravitreal ranibizumabReferral centerCase seriesVEGF injectionIOP increaseYAG capsulotomy
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator
2006
Evaluation of the Clinical Age-Related Maculopathy Staging System
Seddon JM, Sharma S, Adelman RA. Evaluation of the Clinical Age-Related Maculopathy Staging System. Ophthalmology 2006, 113: 260-266. PMID: 16458093, DOI: 10.1016/j.ophtha.2005.11.001.Peer-Reviewed Original ResearchConceptsStages of ARMAge-related maculopathyMaculopathy Staging SystemStaging systemClinical research protocolsClinical practiceRetinal pigment epithelial irregularitiesAdvanced age-related macular degenerationRetinal pigment epithelial detachmentAge-related macular degenerationCross-sectional comparison studyClinical ageSlit-lamp assessmentPigment epithelial detachmentClinical classification systemReliable staging systemResearch protocolSimple grading scalePhotographic gradesExperienced gradersChoroidal neovascularizationClinical examinationEpithelial detachmentGeographic atrophyEpithelial irregularities